Russia's Sputnik V vaccine gets nod from Centre

New Delhi, April 12: Amid India's ongoing Tika Utsav, the government's Subject Expert Committee approved the use of the Russian-made Sputnik-V vaccine. According to the information, the government body has permitted on basis of the strong immunogenicity data.

 

 

 

The decision comes after the Drugs Controller General of India (DCGI)'s Subject Expert Committee (SEC) met today to take up Sputnik V application for Emergency Use Authorisation in India.

 

 

After necessary approval from DCGA, Sputnik-V will be the 3rd vaccine to get emergency use authorisation from the drug regulator after Covishield and Covaxin.

 

 

The Lancet journal has published the late-stage trial results of the vaccine in February. The report indicated that the Russian-made vaccine provided 92 percent protection against COVID-19. The company is also undertaking its Phase III clinical trials in the UAE, India, Venezuela, and Belarus, according to Sputnik-V's website.

 

 

 

 

Sputnik-V claims that it is an affordable vaccine and can be "stored at a temperature of +2 to +8°C ".

 

Last week, the Hyderabad-based pharmaceutical company Dr. Reddy's Laboratories had sought the government's approval for the Sputnik V vaccine to be used in India. The Russian Direct Investment Fund (RDIF) partnered with Dr. Reddy's in September 2020 to conduct clinical trials of Sputnik V in India.

.

.